HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
https://www.blogtalkradio.com/myelomacrowdradio
Gesamtlänge aller Episoden: 14 days 8 hours 1 minute
episode 6: Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center
Many myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Here's a new drug that may help overcome resista
episode 6: Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center
Many myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Here's a new drug that may help overcome resista
episode 8: Myeloma Crowd Radio: Brian McMahon of SparkCures (rescheduled)
How to get into popular myeloma clinical trials
episode 8: Myeloma Crowd Radio: Brian McMahon of SparkCures (rescheduled)
How to get into popular myeloma clinical trials
episode 9: Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer Institute
Mid-Year Review for Multiple Myeloma
episode 9: Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer Institute
Mid-Year Review for Multiple Myeloma
episode 10: Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University
Learn more about the new GSK antibody for relapsed/refractory multiple myeloma
episode 10: Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University
Learn more about the new GSK antibody for relapsed/refractory multiple myeloma
episode 11: Myeloma Crowd: Irene Ghobrial, MD, Dana Farber Cancer Institute
A 50,000 patient and family study for early precursor myeloma conditions
episode 11: Myeloma Crowd: Irene Ghobrial, MD, Dana Farber Cancer Institute
A 50,000 patient and family study for early precursor myeloma conditions